Effects of estrogen on brain development and neuroprotection - Implications for negative symptoms in schizophrenia

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 2, 2003, Pages 83-96

  Rao, M L ^a   Kolsch H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Estradiol 17 ; Gender effect; Glutamate; Negative symptoms of schizophrenia; Neurotoxicity; Serotonin

Indexed keywords

DOPAMINE; ESTRADIOL; ESTROGEN; GLUCOSE; GLUTAMIC ACID; MONOAMINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OXYGENASE;

BRAIN; BRAIN ATROPHY; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN STEM; CADAVER; CEREBROSPINAL FLUID; COGNITION; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; NEUROPROTECTION; NORADRENERGIC SYSTEM; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SHORT SURVEY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0037377075     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00126-9     Document Type: Short Survey

References (104)

1. Aboitiz F., Rodriguez E., Olivares R., Zaidel E. Age-related changes in fibre composition of the human corpus callosum: sex differences. Neuroreport. 7:1996;1761-1764.
2. Aghajanian G.K., Marek G.J. Serotonin induces excitatatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
3. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews. 31:2000;302-312.
4. Ali M., Sahib M.K. Changes in alpha-fetoprotein and albumin synthesis rates and their levels during fetal and neonatal development of rat brain. Brain Research. 282:1983;314-317.
5. Andreasen N.C. Negative symptoms in schizophrenia; definition and reliability. Archives of General Psychiatry. 39:1982;784-788.
6. Andreasen N.C., Smith M.R., Jacoby C.G., Denner J.W., Olsen S.A. Ventricular enlargement in schizophrenia, definition and prevalence. American Journal of Psychiatry. 139:1982;292-296.
7. Berridge M.J., Bootman M.D., Lipp P. Calcium - a life and death signal. Nature. 395:1998;645-648.
8. Beyer C. Estrogen and the developing mammalian brain. Anatomy and Embryology. 199:1999;379-390.
9. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Aschaffenburg G. Handbuch der Psychiatrie. 1911;1-420 Deuticke, Leipzig.
10. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. British Journal of Psychiatry. 174:(Suppl. 37):1999;16-18.
11. Bunney B.G., Bunney W.E., Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J., Bunney B.S., Ciaranello R.D., Davis K.l., Koob G.F., Meltzer H.Y., Schuster C.R., Shader R.I., Watson S.J. Psychopharmacology. The Fourth Generation of Progress. 1995;1205-1214 Raven Press, New York.
12. Carfagno M.L., Hoskins L.A., Pinto M.E., Yeh J.C., Raffa R.B. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (ant)agonists. The Annals of Pharmacotherapy. 34:2000;788-797.
13. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Reviews of Psychiatry. 3:1996;241-253.
14. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? British Medical Journal. 280:1980;66-68.
15. Davila R., Manero E., Zumarraga A.I., Schweitzer J.W., Friedhoff A.J. Plasma homovanillic acid as a predictor of response to neuroleptics. Archives of General Psychiatry. 45:1988;564-567.
16. D'Occhio M.J., Brooks D.E. Effects of androgenic and oestrogenic hormones on mating behaviour in rats castrated before and after puberty. Journal of Endocrinology. 86:1980;403-411.
17. DonCarlos L.L., Handa R.J. Developmental profile of estrogen receptor mRNA in the preoptic area of male and female neonatal rats. Brain Research. 79:1994;283-289.
18. Dörner G., Docke F., Götz F. Male-like sexual behaviour of female rats with unilateral lesions in the hypothalamic ventromedial nuclear region. Endokrinologie. 65:1975;133-137.
19. Downhill J.E. Jr., Buchsbaum M.S., Wei T., Spiegel-Cohen J., Hazlett E.A., Haznedar M.M., et al. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophrenia Research. 42:2000;193-208.
20. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced metabolic activation. Brain Research. 812:1998;65-75.
21. Elsworth J.D., Roth R.H., Redmond D.E. Jr. Does HVA concentration in CSF or plasma reflect central dopamine function in primates? Progress Neuro-psychopharmacology and Biological Psychiatry. 128:(Suppl.):1983;125.
22. Ferretti C., Blengio M., Vigna I., Ghi P., Genazzani E. Effects of estradiol on the ontogenesis of striatal dopamine D1 and D2 receptor sites in male and female rats. Brain Research. 571:1992;212-217.
23. Fitch R.H., Denenberg V.H. A role for ovarian hormones in sexual differentiation of the brain. Behavioral Brain Sciences. 21:1998;311-327.
24. Frisch R. Fatness and fertility. Scientific American. 258:1988;88-95.
25. Garcia-Segura L.M., Cardona-Gomez P., Naftolin F., Chowen J.A. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport. 9:1998;593-597.
26. Gattaz W.F., Vogel P., Riecher-Rössler A., Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry. 36:1994;137-139.
27. Gelernter J., van Kammen D.P. Schizophrenia: instability in norepinephrine, serotonin and gamma-aminobutryric acid systems. International Reviews of Neurobiology. 29:1990;309-347.
28. Goldstein J.M., Link B.G. Gender and the expression of schizophrenia. Journal of Psychiatry Research. 22:1988;141-155.
29. Gridley K.E., Green P.S., Simpkins J.W. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Research. 778:1997;158-165.
30. Green P.S., Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. International Journal of Developmental Neuroscience. 18:2000;347-358.
31. Guivarc'h D., Vincent J.D., Vernier P. Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology. 139:1998;4213-4221.
32. Gur R.C., Gur R.E., Obrist W.D., Hungerbohler J.P., Younking D., Rosen A.D., et al. Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science. 217:1982;659-661.
33. Häfner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Research. 38:1991;125-134.
34. Häfner H., Riecher-Rössler A., an der Heiden W., Maurer K., Fatkenheuer B., Löffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychological Medicine. 23:1993;925-940.
35. Haus-Seuffert P., Meisterernst M. Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB. Molecular Cell Biochemistry. 212:2000;5-9.
36. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular Psychiatry. 6:2001;66-73.
37. Hofman M.A., Swaab D.F. The sexually dimorphic nucleus of the preoptic area in the human brain: a comparative morphometric study. Journal of Anatomy. 164:1989;55-72.
38. Holman S.D., Hutchison R.E., Hutchison J.B. Microimplants of estradiol in the sexually dimorphic area of the hypothalamus activate ultrasonic vocal behavior in male Mongolian gerbils. Hormones and Behavior. 25:1991;531-548.
39. Huber G. Pneumencephalographische und psychopathologische Bilder bei endogenen Psychosen. 1957;Springer, Berlin.
40. Hutchison J.B., Wozniak A., Beyer C., Karolczak M., Hutchison R.E. Steroid metabolising enzymes in the determination of brain gender. Journal of Steroid Biochemistry and Molecular Biology. 69:1999;85-96.
41. Hutchison J.B., Beyer C., Hutchison R.E., Wozniak A. Sexual dimorphism in the developmental regulation of brain aromatase. Journal of Steroid Biochemistry and Molecular Biology. 53:1995;307-313.
42. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience. 249:(Suppl. 4):1999;90-98.
43. James T., Matzelle D., Bartus R., Hogan E.L., Banik N.L. New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. Journal of Neuroscience Research. 51:1998;218-222.
44. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry. 48:2000;641-650.
45. Javitt D.C. Treatment of negative and cognitive symptoms. Current Psychiatry Research. 1:1999;25-30.
46. Kaminski R., Powchick P., Warne P.A., Goldstein M., McQueeney R.T., Davidson M. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Progress in Neuro-psychopharmacology and Biological Psychiatry. 14:1990;271-287.
47. van Kammen D.P., Slawsky R.C. State dependency and dysregulation of norepinephrine activity in schizophrenia. Sen A.K., Lee T. Receptors and Ligands in Psychiatry. 1989;93-126 Cambridge University Press, New Rocelle, Cambridge.
48. van Kammen D.P., Mann L.S., Sternberg D.E., Scheinin M., Ninan P.T., Marder S.R., et al. Dopamine-β-hydroxylase activity and homovanillic acid in spinal fluid of paitents with brain atrophy. Science. 220:1983;974-977.
49. van Kammen D.P., van Kammen W.B., Mann L.S., Seppala T., Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry. 43:1986;978-983.
50. van Kammen D.P., Mouton A., Kelley M., Breeding W., Peters J. Exploration of dopamine and noradrenaline acctivity and negative symptoms in schizophrenia: concepts and controversies. Marneros A., Andreasen N.C., Tsuang M.T. Negative Versus Positive Schizophrenia. 1991;3127-3140 Springer, Berlin.
51. Kaasinen V., Nagren K., Hietala J., Farde L., Rinne J.O. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. American Journal of Psychiatry. 158:2001;308-311.
52. Kawanishi Y., Harada S., Tachikawa H., Okubo T., Shiraishi H. Novel variants in the promoter region of the CREB gene in schizophrenic patients. Journal of Human Genetics. 44:1999;428-430.
53. Kawata M. Roles of steroid hormones and their receptors in structural organization in the nervous system. Neuroscience Research. 24:1995;1-46.
54. Kölsch H., Lütjohann D., Tulke A., Björkhem I., Rao M.L. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y neuroblastoma cells. Brain Research. 818:1999;171-175.
55. Kölsch H., Ludwig M., Lütjohann D., Rao M.L. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17β Journal of Neural Transmission. 108:2001;475-488.
56. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., et al. Brain-derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Molecular Psychiatry. 5:2000;558-562.
57. Kukstas L.A., Domec C., Bascles L., Bonnet J., Verrier D., Israel J.M., et al. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 129:1991;1101-1103.
58. Kulkarni J., de Castella A., Smith D., Taffe T., Keks D.C. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research. 20:1996;247-252.
59. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., et al. Estrogen - a potential treatment for schizophrenia. Schizophrenia Research. 48:2001;137-144.
60. Lane H.Y., Chang Y.C., Chang W.H., Lin S.K., Tseng Y.T., Jann M.W. Effects of gender and age on plasma levels of clozapine and its metabolites, analyzed by critical statistics. Journal of Clinical Psychiatry. 60:1999;36-40.
61. Lephart E.D. A review of brain aromatase cytochrome P450. Brain Research Reviews. 22:1996;1-26.
62. Lindamer L.A., Buse D.C., Lohr J.B., Jeste D.V. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biological Psychiatry. 49:2001;47-51.
63. Lindström L.H. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Research. 14:1985;265-273.
64. Lipton S.A. Janus faces of NFkappaB: neurodestruction versus neuroprotection. Nature Medicine. 3:1997;20-22.
65. Lohr J.B., Underhill S., Moir S., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry. 28:1990;535-539.
66. Losonsczy M.F., Song I.S., Mohs R.C., Mathe A.A., Davidson M., Davis B.M., et al. Correlates of lateral ventricular size in chronic schizophrenia. II. Biological measures. American Journal of Psychiatry. 143:1986;1113-1118.
67. Maclusky N.J., Naftolin F. Sexual differentiation of the central nervous system. Science. 211:1981;1294-1302.
68. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2, pKi values. Journal of Pharmacologcial and Experimental Therapeutics. 251:1989;238-246.
69. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacological Reviews. 43:1991;587-604.
70. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for taridve and l-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry. 34:1993;713-738.
71. Moore R.Y. The anatomy of central neural mechanisms regulating endocrine rhythms. Krieger D.R. Endocrine Rhythm. 1979;63-88 Raven Press, New York.
72. Moriarty P.J., Lieber D., Bennett A., White L., Parrella M., Harvey P.D., et al. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophrenia Bulletin. 27:2001;103-113.
73. van Os J., Walsh E., van Horn E., Tattan T., Bale R., Thompson S.G. Tardive dyskinesia in psychosis: are women really more at risk?, UK700 Group. Acta Psychiatrica Scandinavica. 99:1999;288-293.
74. Pecins-Thompson M., Bethea C.L. Ovarian steroid regulation of serotonin-1A autoreceptor messenger RNA expression in the dorsal raphe of rhesus macaques. Neuroscience. 89:1999;267-277.
75. Potkin S.G., Weinberger D.R., Linnoila M., Wyatt R.J. Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry. 140:1983;21-25.
76. 2+ transients in spines of CA1 pyramidal neurons from hippocampal slices. Journal of Neurophysiology. 81:1999;1404-1411.
77. Pucak M.L., Grace A.A. Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro. Brain Research. 713:1996;44-52.
78. Raap D.K., DonCarlos L., Garcia F., Muma N.A., Wolf W.A., Battaglia G., et al. Estrogen desensitizes 5-HT(1A) receptors and reduces levels of G(z), G(i1) and G(i3) proteins in the hypothalamus. Neuropharmacology. 39:2000;1823-1832.
79. Rao M.L. Biochemische Hypothesen zur Negativ-Symptomatik der Schizophrenie. Möller H.-J., Laux G. Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. 1994;125-139 Springer, Berlin.
80. Rao M.L., Möller H.-J. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Pharmacopsychiatry. 30:1994;160-172.
81. Rao M.L., Gross G., Halaris A., Huber G., Marler M., Strebel B., et al. Hyperdopaminergia in schizophreniform psychosis. A chronobiological study. Psychiatry Research. 47:1993;187-203.
82. Rao M.L., Gross G., Strebel B., Halaris A., Huber G., Bräunig P., et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biological Psychiatry. 35:1994;151-163.
83. Rao M.L., Strebel B., Halaris A., Gross G., Huber G., Bräunig P., et al. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones and cortisol in schizophrenia. Psychiatry Research. 57:1995;21-39.
84. Raynaud J.P., Mercier-Bodard C., Baulieu E.E. Rat estradiol binding plasma protein (EBP). Steroids. 18:1971;767-788.
85. Riecher-Rössler A., Häfner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology. Schizophrenia Bulletin. 20:1994;203-214.
86. Saugstad L.F. The maturational theory of brain development and cerebral excitability in the multifactorially inherited manic-depressive psychosis and schizophrenia. International Journal of Psychophysiology. 18:1994;189-203.
87. van der Schoot P. Effects of dihydrotestosterone and oestradiol on sexual differentiation in male rats. Journal of Endocrinology. 84:1980;397-407.
88. Seeman M.V. Neuroleptic expressed prescription for men and women. Social Pharmacology. 3:1989;219-236.
89. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophrenia Bulletin. 16:1990;185-194.
90. Steinberg J.L., Garver D.L., Moeller F.G., Raese J.D., Orsulak P.F. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Research. 48:1993;93-106.
91. Stahl, S.M., 1996. Essential Psychopharmacology. Cambridge University Press, Cambridge, NY, 257.
92. Stein L., Wise C.D. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroydopamine. Science. 171:1971;1032-1036.
93. Stone D.J., Rozovsky I., Morgan T.E., Anderson C.P., Finch C.E. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. Journal of Neuroscience. 18:1998;3180-3185.
94. Sumner B.E., Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Molecular Brain Research. 59:1998;205-214.
95. Supprian T., Kalus P. Sexual dimorphism of the human brain - a review of the literature. Fortschritte der Neurologie-Psychiatrie FDN. 64:1996;382-389.
96. Swaab D.F., Fliers E. A sexually dimorphic nucleus in the human brain. Science. 228:1985;1112-1115.
97. Szymanski S., Lieberman J.A., Alvir J.M., Mayerhoff D., Loebel A., Geisler S., et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry. 152:1995;698-703.
98. Vedder H., Anthes N., Stumm G., Würz C., Behl C., Krieg J.C. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. Journal of Neurochemistry. 72:1999;2531-2538.
99. Walker P.R.S., Sikorska M. New aspects of the mechanism of DNA fragmentation in apoptosis. Biochemistry and Cell Biology. 75:1997;287-299.
100. Wassink T.H., Nelson J.J., Crowe R.R., Andreasen N.C. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. American Journal of Medical Genetics. 88:1999;724-728.
101. Wilson J.D., Williams R.H. Williams Textbook of Endocrinology. ninth ed. 1998;WBS, Philadelphia.
102. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biological Psychiatry. 45:1999;1512-1515.
103. Young Z., Feng J., Finberg A.A., Greengard P. D2-dopamine receptors induce mitogen-activated protein kinase and CAMP-response element binding phosphorylation in neurons. Proceedings of the National Academy of Science, USA. 96:1999;11607-116012.
104. Zheng X.L., Hendry W.J. III. Neonatal diethylstilbestrol treatment alters the estrogen-regulated expression of both cell proliferation and apoptosis-related proto-oncogenes (c-jun, c-fos, c-myc, bax, bcl-2, and bcl-x) in the hamster uterus. Cell Growth and Differentiation. 8:1997;425-434.